TritonPoint Wealth’s Arcturus Therapeutics ARCT Stock Holding History

TritonPoint Wealth’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-28,072	Closed	-$517K	–	279
2025 Q3	$517K	Hold	28,072	–	–	0.04%	216
2025 Q2	$365K	Hold	28,072	–	–	0.03%	258
2025 Q1	$297K	Hold	28,072	–	–	0.03%	276
2024 Q4	$476K	Hold	28,072	–	–	0.04%	210
2024 Q3	$618K	Hold	28,072	–	–	0.06%	187
2024 Q2	$684K	Hold	28,072	–	–	0.07%	170
2024 Q1	$885K	Hold	28,072	–	–	0.09%	153
2023 Q4	$885K	Buy	+28,072	New	+$667K	0.09%	159

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

TritonPoint Wealth's ARCT Position: Q4 2025 in Review

TritonPoint Wealth sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 28,072 shares — an estimated $517K sold.

TritonPoint Wealth first reported a position in ARCT in Q4 2023 and held it in 8 quarters. The position peaked at $885K in Q1 2024. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

TritonPoint Wealth reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
TritonPoint Wealth sold 28,072 Arcturus Therapeutics shares in Q4 2025, an estimated $517K.
TritonPoint Wealth first reported a position in Arcturus Therapeutics in Q4 2023 and held it in 8 quarters.
TritonPoint Wealth's Arcturus Therapeutics position peaked at $885K in Q1 2024.
120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on TritonPoint Wealth's 13F filing for Q4 2025, filed 20 Jan 2026.